Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits

Wed, 12th Oct 2022 21:46

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Harmony Energy Income Trust PLC - London-based investment company focused on energy projects - Raises GBP15 million in an issue of 15.0 million shares at a price of 100 pence each. Plans to use the funds for the acquisition of solar photovoltaic technology pipeline projects. "The net proceeds of the issue, together with not less than 7 million C shares to be issued to Harmony Energy as consideration, will enable the company to exercise its right of first refusal on these projects and secure them at the attractive entry point agreed pursuant to the pipeline agreement," the company says.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company focused on copper across Australia and Zambia - Completes four drill holes for 488 meters at the Tors Tank prospect, within its BHA project's east zone. Says all four holes have hit targeted cobalt mineralisation zones. Looks forward to remaining assay results. "The drilling campaign has got off to an excellent start, with initial interpretations from the geology team confirming that targeted cobalt zones have been intersected. Moreover, whilst subject to final assay results, the board is delighted to learn that significant pegmatite zones have been intersected which could potentially host rare earth elements," Managing Director Dennis Jensen comments.

----------

AssetCo PLC - London-based advisory and asset management firm - Appoints Numis Securities Ltd to continue with its share repurchase programme. Accelerates its existing GBP7.5 million share repurchase programme.

----------

Condor Gold PLC - mine developer in Nicaragua - Appoints Jim Mellon as non-executive chair. He was non-executive director for several years and is the largest shareholder with a 19% stake.

----------

TomCo Energy PLC - London-based oil explorer in the US state of Utah - Gets a conversion notice from its convertible loan subscriber to convert the remaining GBP175,000 principal amount of the first tranche of the convertible loan, together with GBP75,000 principal amount of the second tranche of the convertible loan and the associated interest on both principal amounts of GBP12,500 into new shares.

----------

Evgen Pharma PLC- Cheshire, England-based drug development company - Starts recruitment for the pharmacokinetic/pharmacodynamic trial in healthy volunteers and decides to start an investigator sponsored clinical study for its glioblastoma programme. Says the purpose of the healthy volunteers study is to examine the performance of Evgen's new enteric coated tablet formulation of lead asset SFX-01.

----------

Coral Products PLC - Manchester-based plastic products maker - Acquires Ecodeck Grids Ltd for a consideration of up to GBP5.6 million. GBP3.4 million will be paid in cash. Further, it will issue of 6.3 million shares in the company at a price of 16 pence per ordinary share. "This acquisition further reinforces our focus on niche, specialist operators in the plastics sector. We have an opportunity to leverage Ecodeck's online platform for other group eco-friendly products. We see significant scope to add value as we integrate the business into the Group - the acquisition continues to broaden our Group's product offering and greatly enhances our available market opportunities. We expect this acquisition will be earnings enhancing in its first year," Executive Chair Joe Grimmond says.

----------

Palace Capital PLC - London-based property investment company - In the first half to September 30, rent collection was 99% and occupancy remained "stable" at 89%, up from 98 and flat at 89% respectively. Completes seven new lettings, six lease renewals and ten rent reviews, generating contracted revenue of GBP2.2 million. "At an operational level the company has made steady progress with its asset management activities and in reducing its level of gross debt and its cost base. However, the significant volatility and uncertainty in financial markets with the prospect of significant increases in interest rates has adversely impacted the commercial property market in relation to investment activity resulting in a re-pricing of assets compared with the position earlier in the year. Therefore, the board has decided to pause the timing of significant property disposals for the time being," Executive Chair Steven Owen says.

----------

Canadian Overseas Petroleum Ltd - Calgary, Canada-based oil and gas company operating in Nigeria and US state of Wyoming - receives gas flaring approval for the Barron Flats Shannon unit from the Wyoming Oil and Gas Conservation Commission at a hearing.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.